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ABSTRACT
Mesothelin is a tumor differentiation antigen expressed by epithelial tumors, 
including pancreatic cancer. Currently, mesothelin is being targeted with an antibody-
drug conjugate (ADC) consisting of a mesothelin-specific antibody coupled to a highly 
potent chemotherapeutic drug. Considering the toxicity of the ADC and reduced 
accessibility of pancreatic tumors, non-invasive imaging could provide necessary 
information. We therefore developed a zirconium-89 (89Zr) labeled anti-mesothelin 
antibody (89Zr-AMA) to study its biodistribution in human pancreatic tumor bearing 
mice. Biodistribution and dose-finding of 89Zr-AMA were studied 144 h after tracer 
injection in mice with subcutaneously xenografted HPAC. MicroPET imaging was 
performed 24, 72 and 144 h after tracer injection in mice bearing HPAC or Capan-2. 
Tumor uptake and organ distribution of 89Zr-AMA were compared with nonspecific 
111In-IgG. Biodistribution analyses revealed a dose-dependent 89Zr-AMA tumor uptake. 
Tumor uptake of 89Zr-AMA was higher than 111In-IgG using the lowest tracer dose. 
MicroPET showed increased tumor uptake over 6 days, whereas activity in blood pool 
and other tissues decreased. Immunohistochemistry showed that mesothelin was 
expressed by the HPAC and CAPAN-2 tumors and fluorescence microscopy revealed 
that AMA-800CW was present in tumor cell cytoplasm. 89Zr-AMA tumor uptake is 
antigen-specific in mesothelin-expressing tumors. 89Zr-AMA PET provides non-
invasive, real-time information about AMA distribution and tumor targeting.
INTRODUCTION
Pancreatic cancer is one of the most aggressive 
tumor entities, with a dismal prognosis. Despite advances 
in treatment of solid tumors, pancreatic cancer has a 5 year 
survival rate of only 6% and a median survival of about 
6 months [1]. This poor prognosis is due to its advanced 
stage at diagnosis and limited curative treatment options.
Until now chemotherapy and targeted agents have 
yielded only modest effects [2]. This has stimulated 
a search for new approaches; one such approach is 
the antibody-drug conjugate (ADC), which consists 
of a specific antibody armed with a highly potent 
chemotherapeutic drug that will be released after 
internalization. Mesothelin might serve as a target 
for ADCs. It is a tumor differentiation antigen highly 
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expressed by cells of many epithelial cancers, with limited 
expression in normal human tissues [3]. Mesothelin is 
overexpressed in mesothelioma, ovarian cancers, and in 
70–100% of pancreatic adenocarcinomas [4, 5]. 
Interestingly, its expression in normal tissues is limited to 
mesothelial cells on pleura, pericardium and peritoneum 
[6, 7]. A number of early clinical results suggest the 
validity of using mesothelin as target. In a phase II study 
with the anti-mesothelin immunotoxin SS1P combined 
with pentostatin and cyclophosphamide, three out of 
10 evaluable patients showed major regression [8]. 
In addition, in a phase I study combining SS1P with 
pemetrexed and cisplatin 12 out of 20 patients had a partial 
response and three showed stable disease [9].
The precise dosing of drugs and selection of patients 
for mesothelin directed therapy could benefit from non-
invasive visualization of anti-mesothelin antibody 
(AMA) to quantify antibody uptake in tumor lesions, 
and ultimately to relate this to anti-tumor effects of 
mesothelin-targeting ADC. Labeling AMA with long-lived 
positron zirconium-89 (89Zr) might allow non-invasive 
tracking using PET. 89Zr-labeled antibodies have already 
been studied in preclinical and clinical setting [10, 11].
The aim of this study was to develop and 
evaluate 89Zr-labeled AMA for non-invasive tracking of 
biodistribution towards pancreatic tumors and organs 
of interest in mice. In addition, a near infrared (NIR) 
fluorescent dye (IRDye 800CW) was labeled to AMA to 
investigate tracer distribution at cellular level.
RESULTS
Conjugation, 89Zr labeling and quality control 
of AMA
Size-exclusion high-performance liquid 
chromatography (SE-HPLC) analysis indicated a 
good conjugation of AMA to the chelator tetrafluorphenol 
N-succinyldesferal (TFP-N-sucDf, VU Medical Center). 
The reaction started with desferal-antibody ratios (DfAR) 
of 2:1 and 5:1 and resulted in an effective conjugation 
of 69% and 65% respectively, and therefore a true 
DfAR of 1.3:1 and 3.5:1. Quality control also showed 
less than 5% aggregates of the conjugated antibody. 
N-suc-Df-TFP-AMA was labeled with 89Zr; the resulting 
89Zr-N-sucDf-AMA is hereafter referred to as 89Zr-AMA. 
Labeling resulted in a high radiochemical efficiency of 
93.4% ± 2.3% (n = 5), without further purification, and 
a high specific activity (>500 MBq/mg). The 1.3:1 DfAR 
obtained a maximum specific activity of 200 MBq/mg, 
however, this is insufficient to label the amount of 
radiation needed for microPET scans for all the AMA 
doses of interest. Therefore the 3.5:1 DfAR was used in 
further experiments.
89Zr-AMA was radiochemically stable in solution 
(0.9% NaCl) when stored at 4 and 20°C for over 168 h. 
Protein-bound 89Zr decreased minimally; from 98.3% to 
98.0% after storing it for 7 days at 4°C, and from 98.3% 
to 96.4% after 7 days at 20°C (Supplementary Figure 1A).
DfAR conjugation in ratios of 1.3:1 or 3.5:1 did 
not affect binding affinity of AMA (P < 0.05, Figure 1). 
Immunoreactivity assay of 89Zr-AMA showed ~50% 
inhibition of the maximum binding of 14 nM AMA 
for competition of extracellular domain of mesothelin 
binding of 14 nM 89Zr-AMA, indicating a fully preserved 
immunoreactivity.
Dose-escalation and biodistribution studies
Biodistribution studies in mice with HPAC tumors 
showed specific tumor uptake of 89Zr-AMA compared 
to nonspecific control for all three doses of 10, 25, and 
100 μg (P < 0.05, Figure 2). Nonspecific IgG was labeled 
with 111In in order to be able to distinguish between 
nonspecific uptake and specific 89Zr-AMA uptake in the 
same mouse. This co-injection of tracers allows correcting 
for potential inter-individual differences. At 144 h after 
injection, the highest percentage tumor uptake was seen in 
the 10 μg dose group which was almost 4 times higher than 
nonspecific control (14.2% ID/g 89Zr-AMA vs. 3.7%ID/g 
111In-IgG; P < 0.05, Figure 2 and Supplementary Table 1). 
Figure 1: ELISA assay of binding affinity for mesothelin extra cellular domain with AMA conjugated to chelator, 
ratio 1:1.3 (yellow) and ratio 1:3.5 (red) compared to control (AMA, black). N = 3 for each ratio. X-axis depicts the amount 
of antibody added in nmol/mL; the Y-axis represents the optical density of the fluorescent signal at 450 nm.
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Tumor uptake decreased with increasing doses of 
AMA (P < 0.05, one way analysis of variance) from 
14.2 ± 2.5%ID/g with 10 μg dose, to 11.1 ± 0.6%ID/g 
with 25 μg dose, and 7.5 ± 1.1%ID/g with 100 μg dose 
(Figure 2). Ex vivo analysis of isolated organs indicated 
a normal distribution of 89Zr-AMA and 111In-IgG. Both 
tracers showed a similar uptake pattern in most organs 
in all groups of mice, with few exceptions. 89Zr-AMA 
tumor uptake was higher than 111In-IgG with every dose 
(respectively 3.8, 2.8, and 1.5 fold higher), indicating 
tumor specific uptake. Bone also showed a 3.5 fold higher 
activity for 89Zr-AMA than nonspecific control. At 10 μg 
89Zr-AMA tumor-to-blood ratio was 3.08 ± 0.55 and 
tumor-to-muscle ratio 15.57 ± 5.61. With increasing doses 
these ratios decreased, indicating dose dependent and 
saturable tracer distribution.
MicroPET and IVIS imaging
Based on results from the dose-escalation 
biodistribution study 10 μg 89Zr-AMA was used 
for imaging experiments. MicroPET scans showed 
homogeneous 89Zr-AMA tracer uptake within the tumors 
at each time point. Tumor uptake increased visibly 
over time, whereas activity in blood pool decreased 
(Figure 3A, 3C).
Figure 2: Tumor uptake of 10, 25 and 100 μg of 89Zr-AMA (white bars), compared to a same dose of co-injected non-
specific 111In-IgG (black bars). N = 6 for each dose. The X-axis indicates the doses tested; the Y-axis indicates the percentage of the 
injected dose that accumulated in tumor corrected for tumor weight in grams. *P < 0.05.
Figure 3: MicroPET imaging data from tumor-bearing mice injected with 10 μg 89Zr-AMA, 5 MBq (n = 6). Representative 
coronal imaging results of one mouse 24 h after injection (left), 72 h (middle) and 144 h (right) bearing A. a HPAC tumor or B. Quantification 
of activity uptake (SUVmean) in tumor and organs of interest over time in HPAC-bearing mice C. a Capan-2 tumor, tumors indicated by 
arrow, color scale depicting SUVmean values from 1 to 2.5. D. or Capan-2-bearing mice.
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Tumor accumulation over time was demonstrated 
by the mean of standardized uptake value (SUVmean) 
quantification (Figure 3B, 3D). For HPAC tumors it 
increased from 1.09 ± 0.24, to 1.51 ± 0.29, and 1.68 ± 0.33 
from 24 h to 72 and 144 h respectively. For Capan-2 
tumors uptake increased from 0.70 ± 0.18, to 1.18 ± 0.32, 
and 1.40 ± 0.41 at 24, 72, and 144 h after tracer injection. 
Ex vivo 89Zr-AMA uptake proved to be tumor-specific 
in both cell lines (Figure 4A, 4B and Online Resource, 
Supplementary Table 1), and tumor uptake was consistent 
with imaging data as %ID/g correlated with SUVmean (see 
Supplementary Figure 2). 89Zr-AMA tumor uptake was 
similar for the HPAC and Capan-2 xenografts (P = 1.000), 
and quantification of tumor, liver, spleen, and kidney 
showed comparable results for both cell lines.
Binding affinity of the AMA molecule for 
mesothelin ECD was preserved after labeling with 800CW. 
Of the two ratios (Dye:mAb) tested, the 2:1 label ratio 
Figure 4: Activity of individual organs containing 89Zr-AMA (white bars) and co-injected non-specific 111In-IgG 
(black bars), indicating specific tumor uptake of 89Zr-AMA in HPAC tumors (a) and Capan-2 tumors (b) *P < 0.05. 
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showed no aggregation over time, where the 4:1 ratio did 
show visible precipitation of labeled protein. Whole body 
fluorescence imaging of mice showed substantial uptake 
of AMA-800CW in tumor (Figure 5A) and accumulation 
over time (Figure 5B).
FACS analyses cell lines, histology and 
immunohistochemistry tumors
Mesothelin expression was observed in both HPAC 
and Capan-2 cells and not in H441 control (data not 
shown). Mesothelin expression was less pronounced in 
HPAC cells than Capan-2.
Hematoxylin-eosin (H&E) staining of tumors showed 
that they consisted purely of tumor tissue and that Capan-2 
tumors are more differentiated than HPAC tumors (data 
not shown). All tumors contained viable tumor cells as 
well as areas of necrosis due to duct formation, typical 
for pancreatic tissue. Mesothelin staining was stronger in 
Capan-2 tumors than in HPAC tumors. Mesothelin staining 
was present in tumor nests and most strongly expressed at 
the apical side of tumor cells surrounding ducts (Figure 6A). 
Fluorescence microscopy revealed that 800CW is mainly 
located in the cytoplasm of tumor cells (Figure 6B and 6D).
DISCUSSION
This study shows that it is possible to visualize 
subcutaneously implanted human pancreatic tumors in mice 
noninvasively over time with the PET tracer 89 Zr-AMA. 
The results indicate a specific mesothelin-driven tumor 
uptake of targeted 89Zr-labeled antibody which visualizes 
human mesothelin expressing pancreatic adenocarcinoma 
in real time.
The biodistribution study showed an increase in tumor 
uptake over time; on average an 89Zr-AMA tumor uptake of 
14.2% ID/g was seen at 144 h after tracer injection. This 
may seem a rather low uptake, but a recent study using an 
111In-labeled anti-ERC/mesothelin mouse monoclonal 
IgG2a did not exceed 5.8%ID/g in the tumor at any time 
point of 24, 48 or 96 h [12]. The differences between these 
studies are likely the consequence of differences in tumor 
exposure given differences in pharmacokinetics (PK) of 
the antibodies. Liver showed a relatively high activity with 
111In-labeled antibody compared with tumor (respectively 15 
versus 5.8%ID/g at 96 h), indicating clearance, whereas our 
89Zr-AMA showed better PK in relation to tumor specificity 
and blood accumulation, and lower non-specific clearance. 
This may be explained by the relatively low and controlled 
conjugation ratio of TFP-N-sucDesferal to AMA, minimizing 
the possible alterations in PK properties of the antibody.
We could accurately visualize tracer tumor uptake 
in two models of xenografted pancreatic adenocarcinoma 
tumors with 89Zr-AMA PET. 89Zr-AMA PET showed 
specific binding to the target with an increase in 
radioactivity in tumor over time, while the amount of 
radioactivity decreased in normal organs. Both xenograft 
types showed similar results despite the different 
mesothelin expression. This may be due to the fact that the 
tracer dose was below the saturation limit of the target, or 
the fact that different internalization rates might cancel out 
different cell-surface levels. Tumor-uptake of the tracer 
exceeded the uptake in surrounding tissue, resulting in a 
good tumor-to-background ratio. Uptake of control did not 
exceed uptake in surrounding tissues, making it possible 
to differentiate between specific and non-specific uptake.
Mesothelin was expressed on cell membrane 
as indicated by immunohistochemistry (IHC) data. 
Fluorescent microscopy of AMA-800CW suggests that 
the tracer is internalized, although target expression on 
membrane could not be visualized as the Hoechst staining 
washed away any of the membrane-bound AMA-800CW.
MicroPET data indicated a relatively high activity 
in joints of the mice of 8.5% with 89Zr-AMA but not 
Figure 5: Fluorescence imaging data from HPAC-bearing mice injected with 100 μg AMA-800CW (n = 10). 
A. Representative sagittal fluorescence imaging results of one mouse 24 h after tracer injection (left), 72 h (middle) and 144 h (right). The 
tumor is indicated by an arrow. B. Relative tumor uptake in tumor to background ratio (TBR) over time.
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with 111In-IgG, indicating an 89Zr-specific mechanism. Bone 
uptake of 89Zr might be due to trans-chelation of 89Zr from 
AMA to plasma proteins or AMA catabolites, and from 
there deposition in bone [13]. 89Zr specifically accumulates 
in mineralized constituents, like epiphysis [14]. This 
89Zr-related, antibody non-specific uptake in bone is 
observed in rodents [15]. However, it has no clinical 
consequences for imaging in humans, as clinical imaging 
studies show no visible bone uptake on PET scans [16].
Radiolabeling the naked antibody of an ADC can 
provide interesting information concerning accessibility 
of the tumor for antibodies and availability of the target in 
tumors. Using 89Zr-PET to better understand the properties 
of a therapeutic antibody has been described previously 
[17]. This is especially important for ADCs, as they are 
not only dependent on the accessibility of the tumor, but 
also on the extent and internalization of target present. 
A trial is analyzing whether an 89Zr-trastuzumab PET 
imaging can predict which patients will not respond to the 
ADC trastuzumab-DM1. A preliminary report indicated 
that a combination of pre-treatment, 89Zr-trastuzumab 
PET imaging, and early 2[18F]fluoro-2-deoxy-D-glucose 
Figure 6: Immunohistochemical staining for mesothelin of HPAC tumor material from mice injected with 100 μg 
AMA-800CW (tumor harvested 144 h after injection). A. A representative brightfield image (400x) of a tumor with an IHC 
staining for mesothelin. B. Fluorescence microscopy at 800 nm for IRDye 800CW labelled to AMA; C. at 460 nm for DAPI staining, D. and 
overlay of fluorescent images.
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positron emission tomography–computed tomography 
(FDG-PET/CT), with response assessment after 1 cycle 
seems potentially capable to identify patients unlikely to 
show a metabolic response after 3 cycles of T-DM1 [18].
Studying mesothelin with molecular imaging in 
the clinic may be increasingly of interest giving the 
increment of treatment options tested that use mesothelin 
as a target and the broad range of tumor that can express 
mesothelin [19].
Mesothelin was targeted with a SPECT tracer 
namely an 111In-labeled chimeric antibody. In all patients 
a tumor-to-background ratio (TBR) of at least 1.2 was 
observed [20]. Our findings with 89Zr-AMA were also 
translated to a clinical trial. This tracer should potentially 
make it easier to quantify tracer uptake than the SPECT 
tracer. We GMP-produced 89Zr-AMA for a phase I study 
of a mesothelin-targeting ADC in pancreatic and ovarian 
cancer patients [21]. In the main study patients received 
the ADC study drug comprising this AMA armed with the 
anti-mitotic drug MMAE. In a side study patients received 
baseline 89Zr-AMA-PET scans before starting ADC 
treatment. These PET scans were performed to quantify 
antibody uptake in pancreatic and ovarian tumor lesions 
and ultimately to relate this uptake to anti-tumor effects 
(http://ClinicalTrials.gov identifier: NCT01832116).
These findings highlight the ability of 89Zr-AMA 
PET to provide non-invasive, real-time information about 
AMA distribution and tumor targeting and argue for an 




All applicable international, national and/or 
institutional guidelines for the care and use of animals 
were followed.
Conjugation, 89Zr labeling of AMA, and 111In 
labeling of IgG
Anti-mesothelin humanized IgG1 monoclonal 
antibody was conjugated with TFP-N-sucDf, at start DfAR 
of 2:1 and 5:1. These ratios were chosen based on previous 
experience [10, 11], a DfAR of 2:1 obtains clear images 
in the clinic, but a higher specific activity is needed for 
animal experiments, therefore a DfAR of 5:1 was made. 
Both DfARs were tested for suitability and labeled with 
clinical-grade 89Zr-oxalate (IBA Molecular) as described 
previously [22]. 89Zr-N-sucDf-AMA is hereafter referred 
to as 89Zr-AMA.
N-sucDf-AMA and 89Zr-AMA were analyzed 
for conjugation ratios, aggregation and radiochemical 
purity by SE-HPLC. Storage stability of 89Zr-AMA 
was tested in 0.9% NaCl at 4 and 20°C by determining 
protein-bound radioactivity using trichloroacetic acid 
(TCA) precipitation. Before storage the sample was 
purified by ultra filtration. TCA precipitation was 
performed in PBS with 0.5% human serum albumin 
(Sanquin) and 20% TCA. Radioactivity in precipitate 
and supernatant was determined by a calibrated well-type 
γ-counter (LKB Instruments).
Immunoreactivity of N-sucDf-AMA was tested with 
an ELISA assay with conjugated and unconjugated AMA. 
The extracellular domain (ECD) of mesothelin (provided 
by Genentech) was used to coat a 96-well plate (10 μg/mL, 
Nunc MaxiSorp, Thermo Fisher Scientific).
Immunoreactivity of radiolabeled antibody was 
tested as described earlier [10]. The assay was performed 
with unlabeled and unconjugated AMA and 89Zr-AMA 
using ECD of mesothelin as target. Unlabeled AMA 
was added in a logarithmic concentration range of 
1 ng/mL – 1 mg/mL, while 89Zr-AMA was kept at a fixed 
concentration of 1000 ng/mL.
Human IgG served as a nonspecific control in the 
in vivo experiments. To be able to differentiate between 
AMA and IgG, 111In was chosen as radiolabel for IgG. 
This allowed co-injection of tracer and control in the 
same animal, making the animal its own control and 
reduced the number of animals needed. Human IgG 
(Sanquin) was conjugated to 2-(4-isothiocyanatobenzyl)-
diethylenetriaminepenta-acetic acid (p-SCN-Bn-DTPA) 
and radiolabeled with 111InCl3 (Mallinckrodt) on day of 
use as published earlier [23].
Cell lines
Human pancreatic tumor cell lines HPAC and 
Capan-2 (American Type Culture Collection) were 
cultured in RPMI 1640 medium (Invitrogen) with 10% 
heat-inactivated fetal calf serum (Bodinco BV) at 37°C 
in a fully humidified atmosphere containing 5% CO2. 
Short tandem repeat (STR) profiling (BaseClear) affirmed 
identity. Cell lines were quarantined until screening for 
microbial contamination and mycoplasma had been 
performed; these tests were negative. In all experiments 
mice were inoculated subcutaneously with 5 × 106 HPAC 
or Capan-2 cells. For analysis of receptor expression, cells 
were incubated with anti-human mesothelin phycoerythrin 
(catalog number: FAB32652P, R&D systems). Human 
lung adenocarcinoma epithelial cell line H441 (American 
Type Culture Collection) served as negative control. 
Membrane receptor expression was analyzed using flow 
cytometry (FACSCalibur, BD Biosciences) with Winlist 
software 6.0 (Verity Software House).
Dose escalation and biodistribution studies
Animal experiments were conducted using male 
athymic mice (BALB/cOlaHsd-Foxn1nu, Harlan). Tumor 
cell inoculation, tracer injection and microPET imaging 
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were performed using isoflurane in medical air inhalation 
anesthesia (induction 5%, maintenance 2%). At 6–8 weeks 
of age the mice were injected subcutaneously in the left 
flank with HPAC cells in 0.2 mL of 1:1 growth medium 
and Matrigel (BD Bioscience). Tumor growth was 
estimated with caliper measurements. Mice were used 
for experiments when tumors measured at least 100 mm3, 
~2 weeks after tumor inoculation.
Biodistribution studies were conducted in mice 
bearing HPAC xenograft tumors to evaluate mesothelin-
specific tumor uptake and dose-dependent tumor uptake 
of AMA. 89Zr-AMA and 111In-IgG were compared for 
biodistribution in 3 dose groups: 10, 25, or 100 μg 
(approximately 0.5, 1.2 and 5.0 mg/kg body weight) of 
both proteins. Each dose was administered to 6 mice 
intravenously in the penile vein, with a co-injection 
of the same dose of nonspecific control, both labeled 
with ± 1 MBq of respectively 89Zr and 111In. Animals 
were sacrificed 144 h after tracer injection and organs 
were excised, rinsed for residual blood, weighed, and 
counted for radioactivity. Tissue activity was expressed 
as percentage injected dose per gram tissue (%ID/g), 
with an assumption of tissue density of 1 g/cm3 [24]. 
All data were corrected for physical decay using known 
standards. Subsequently, tumors were split, formalin-fixed 
and paraffin-embedded, and stored at −80°C for ex vivo 
mesothelin measurements.
MicroPET and IVIS imaging
Based on dose escalation and biodistribution 
experiments, a dose of 10 μg was used in animal imaging 
and distribution studies. For imaging a microPET Focus 
220 rodent scanner (CTI Siemens) was used. Two groups 
of 6 animals were subcutaneously injected with either 
HPAC or Capan-2 cells.
Approximately 2 weeks after tumor inoculation, 
10 μg of AMA labeled with 5 MBq 89Zr was injected via 
the penile vein, with a co-injection of 10 μg of IgG labeled 
with 1 MBq 111In.
Static images of animals were acquired with 
an acquisition time of 15–60 min at 24, 72 and 144 h 
after tracer injection. Images were corrected for scatter 
and attenuation. After image reconstruction, in vivo 
quantification was performed with AMIDE (A Medical 
Image Data Examiner) software (version 1.0.2; Stanford 
University) [25] and tumor accumulation was calculated 
as the mean of standardized uptake value (SUVmean). For 
region-of-interest (ROI) measurements, tumor volumes 
were manually drawn as described earlier [26], based on 
tumor weight measured ex vivo, assuming a tissue density 
of 1 g/mL. Animals were sacrificed after the last scan 
(t = 144 h) and organs were excised, rinsed for residual 
blood weighed and counted for radioactivity. Tumors were 
split, one part formalin-fixed and paraffin-embedded, and 
one part stored at -80°C for ex vivo measurements.
AMA localization within tumor was studied 
using fluorescent labeled AMA. For production of the 
fluorescent tracer 1000 μg AMA was labeled with IRDye 
800CW-NHS (LI-COR Biosciences) in a ratio of 2:1 and 
4:1 (Dye:mAb) according to manufacturer’s protocol. 
Final product was analyzed as described previously [26]. 
Immunoreactivity of fluorescent AMA was tested with 
an ELISA assay. A ratio of 2:1 was used in the animal 
experiments.
Ten mice were injected subcutaneously with HPAC 
cells. Approximately 2 weeks after tumor inoculation, 
when tumors measured at least 200 mm3, fluorescent 
imaging agent (100 μg AMA-800CW) was injected via 
the penile vein. Fluorescence images using IVIS Spectrum 
were obtained 24 (n = 10), 72 (n = 7) and 144 h (n = 4) 
after tracer injection. Following each scan, a number of 
mice were sacrificed and tumors were excised for ex vivo 
analysis.
Fluorescence images were retrieved by using 
excitation wavelengths of 745 nm and a filter of 
800 nm. Data were analyzed using Living Image 4.3.1 
software (Caliper Life Sciences). To determine tumor-
to-background ratios (TBR) from NIR fluorescent 
images, tumor boundary was set as ROI, and the ratio 
was calculated by comparing tumor uptake with shoulder 
muscle of the animal as background value.
Ex vivo tissue analysis
Formalin-fixed paraffin-embedded tumors were 
stained using hematoxylin-eosin (H&E) for histology, 
and mesothelin expression was immunohistochemically 
stained with an anti-mesothelin isoform 1 antibody (clone 
#420404; R&D Systems).
For fluorescence microscopy, tumor slides were 
stained with Hoechst 33258 (Invitrogen).
Statistical analysis
Data are presented as mean ± SD. Statistical 
analysis was performed using the Mann-Whitney test 
for non-parametric data (Prism, version 5; GraphPad 
Software). A P value of 0.05 was considered significant. 
The correlation between quantified in vivo small-animal 
PET images and ex vivo biodistribution data was estimated 
by linear regression.
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